Analysing multiple types of molecular profiles simultaneously:
  connecting the needles in the haystack by Menezes, Renée et al.
ar
X
iv
:1
51
0.
02
32
9v
1 
 [s
tat
.M
E]
  8
 O
ct 
20
15
Menezes et al.
RESEARCH
Analysing multiple types of molecular profiles
simultaneously: connecting the needles in the
haystack
Rene´e X Menezes1*, Leila Mohammadi2, Jelle J Goeman3 and Judith M Boer4,5
Abstract
Background: It has been shown that a random-effects framework can be used to test the association between
a gene’s expression level and the number of DNA copies of a set of genes. This gene-set modelling framework
was later applied to find associations between mRNA expression and microRNA expression, by defining the
gene sets using target prediction information.
Methods and Results: Here, we extend the model introduced by Menezes et al.(2009) to consider the effect
of not just copy number, but also of other molecular profiles such as methylation changes and
loss-of-heterozigosity (LOH), on gene expression levels. We will consider again sets of measurements, to
improve robustness of results and increase the power to find associations. Our approach can be used
genome-wide to find associations, yields a test to help separate true associations from noise and can include
confounders.
We apply our method to colon and to breast cancer samples, for which genome-wide copy number,
methylation and gene expression profiles are available. Our findings include interesting gene
expression-regulating mechanisms, which may involve only one of copy number or methylation, or both for the
same samples. We even are able to find effects due to different molecular mechanisms in different samples.
Conclusions: Our method can equally well be applied to cases where other types of molecular
(high-dimensional) data are collected, such as LOH, SNP genotype and microRNA expression data.
Computationally efficient, it represents a flexible and powerful tool to study associations between
high-dimensional datasets. The method is freely available via the SIM BioConductor package.
Keywords: gene set; integration; “p >> n”; global test; penalized regression
Background
The wealth of omics data being currently produced
raises the need for efficient and flexible models to anal-
yse these data. One typical objective is to understand
which molecular changes affect gene expression lev-
els or, if available, protein expression levels. Molec-
ular profiles reliably measured currently include DNA
methylation and copy number, sequence information
including SNP and loss-of-heterozigosity (LOH) infor-
mation, as well as microRNA expression levels. All
these are known to be involved in gene expression reg-
ulation.
Many methods have so far been proposed for find-
ing associations between two omics data sets (for an
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overview see [1]). These enable us to study for exam-
ple which copy number changes affect gene expression
levels, or alternatively which methylation changes af-
fect gene expression, and to which extent they do so.
Such findings can for example shed light onto onco-
genic mechanisms. One such method has been pro-
posed by Menezes et al.[2], whereby a statistical test
is used to for example assess the association between
gene expression and the copy number of a genomic
region around it. In that work, the authors showed
the power gain to find associations yielded by consid-
ering sets of measurements, rather than considering
only associations between pairs of features, as done
elsewhere[3].
Methods have also been proposed for the joint anal-
ysis of microRNA expression and mRNA expression
profiles. In this context, many microRNAs can tar-
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get the same mRNA, and one microRNA can target
multiple mRNAs. So it makes sense to consider target
prediction information while looking for associations
between mRNA and microRNA expression levels. van
Iterson et al.[4] use the method proposed by Menezes
et al.[2], with gene sets now defined by various tar-
get prediction tools. It is then shown that the method
has power to find associations that are sucessfully val-
idated, in spite of limited sample size. They also show
that predicted associations using sets of features lead
to more robust, and thus more reliable, results, in this
case with a higher validation rate, than associations
predicted using pairs of features (i.e. one miRNA and
one mRNA at a time). This is in agreement of findings
from Menezeset al.[2]. The extra robustness is brought
in by the fact that the impact on small effects ob-
served for specific genes must be observed for at least
a considerable subset of genes, before they become sig-
nificant.
With multiple types of molecular profiles measured,
it makes sense to consider methods for analysing all
of them together. Only a few of the integrated anal-
ysis methods so far proposed have been extended to
handling more than two data sets. Methods proposed
by Waaijenborg et al.[5] and by Witten et al.[6] use a
sparse canonical correlation framework. As such, they
are of an exploratory nature, aiming at finding sets of
covariates from the various data sets which are most
correlated.
Here we extend the integrated analysis method pro-
posed by Menezes et al.[2] to handle multiple high-
dimensional data sets. The aim is to test for associ-
ation between one type of molecular profile (mRNA,
say) and other types (copy number and methylation,
say), the latter represented by sets of probes, rather
than individual ones. Under the null hypothesis, no as-
sociation exists between mRNA and either copy num-
ber or methylation, in our example. The use of sets
makes for a robust and powerful method: robust, be-
cause noise originating from individual probes is ig-
nored; and powerful, because subtle associations found
between mRNA and multiple methylation probes are
detectable as the probability of seeing many of these
small associations together by chance will be consid-
ered small, which would be ignored if they were consid-
ered separately. Given the high-dimensionality of the
problem, the fact that our method evaluates statisti-
cal significance is crucial to help separate noise from
true associations. Moreover, since our method uses a
regression framework, it can take confounders into ac-
count. As the original method, it is thus a flexible,
powerful and efficient method to analyse jointly many
omics data sets.
This paper is organized as follows. In the Methods
section we present the statistical test for associations
between multiple gene sets and a response. In the Re-
sults section we illustrate the workings of our method
under various types of associations between data sets
with a simulation study. We also apply our method to
sets of TCGA samples: 125 of colon cancer and 173
of breast cancer, for which copy number, methylation
and gene expression profiles are available.
Methods
The integrated analysis model
Menezes et al.[2] have proposed using score tests to
find associations between a response (say, the expres-
sion levels of a gene) and a set of covariates (say, the
genomic copy number measured at multiple loci on the
same chromosome arm as the gene). Let us represent
by Yni the expression for gene i, and by Xnj the ge-
nomic copy number for gene j, where i = 1, . . . , I and
j = 1, . . . , J represent the sets of probes used, and
n = 1, . . . , N indexes the sample. Note that it is as-
sumed that measurement sets {Yi}, {Xj} are available
per sample, although it is not necessary that both sets
of probes correspond to the same loci. Then we write,
for any given i,
E (Yni) = h

α+
J∑
j=1
βjXnj

 , n = 1, . . . , N, (1)
where h(.) is a given inverse link function and {βj} ∼
N (0, τ), making model (1) a random-effects model.
From now on, we consider observations Yi for a single
gene indexed by i, but we omit the index i for clarity.
The approach proposed by Menezes et al.[2] fo-
cuses not on fitting model (1) directly, but on testing
whether or not the association between Y and {Xj} is
statistically significant, for each gene expression probe
Y . This is done by making use of the global test [7]. In
this framework, under the null hypothesis that Y is not
associated with the set {Xj}, we have Var(β) = τ = 0.
On the other hand, when Y displays association with
variables in {Xj}, then some of the βj will be non-zero,
and thus Var(β) > 0. Specifically, the global test is a
score test for the hypotheses
H0 : Var(β) = 0 vs. Ha : Var(β) 6= 0,
first proposed by [8] and later applied to the context of
testing association between a molecular profile and a
clinical variable by Goeman et al.[7]. Goeman also fur-
ther extended the test to generalized linear models and
Cox regression models [9], and showed that it is the lo-
cally most powerful test against a set of alternatives
often of interest [10]. Let us define rn =
∑
j βjXnj,
the part of the linear predictor that depends on the
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data, r = (r1, r2, . . . , rN )
t, and X an N × J matrix
containing all observations for the covariates. Then a
statistic to test the hypotheses above was proposed by
Goeman et al.[7] as
Q(X) ∝
(Y − µ)tXXt(Y − µ)
(Y − µ)t(Y − µ)
, (2)
or in its standardized form
T =
Q(X)− E [Q(X)]√
Var [Q(X)]
. (3)
Goeman et al.[7] have also shown that E(Q) =
trace(XXt)/J and Var(Q) = 2 trace[(XXt)2]/J2.
As Q is a (scaled) quadratic form, its distribution is
asymptotically equivalent to a weighted sum of 1 d.f.
chi-square distributions (see [11]) and, for some special
cases such as the linear model, numerical integration
can be used to find its cumulative distribution function
in finite-sample problems [10]. Note that the numer-
ator of the test statistic Q(X) is a quadratic form
involving the covariances between the random effects
{rn}, given by XXt up to a constant.
Applying this test generates one p-value per gene ex-
pression variable Y . For a set of gene expression probes
{Yi, i = 1, . . . , I} a list of p-values is obtained, where
i indicates different probes, loci or genes. Multiple-
testing correction must be applied before drawing con-
clusions. Individual contributions of each copy number
variable Xj on the dependent variable Yi can be com-
puted, generating an overview of association patterns
between copy number and gene expression profiles.
Extension to two sets of covariates
Assume now that a second set of covariates {Zk} is
observed, and there is interest in studying the associa-
tion between both covariate sets and the response Yi.
Now model (1) becomes
E (Yni) = α+
J∑
j=1
βjXnj+
K∑
k=1
γkZnk, n = 1, . . . , N, (4)
where {βj} ∼ N (0, τ) and {γk} ∼ N (0, θ), so that
model (4) still is a random-effects model, and where we
have assumed for simplicity that h(x) = x. Similarly to
the single covariate-set case, under the null hypothesis
no association exists between either Y and {Xj}, or
Y and {Zk}. In this case, obviously the variances τ, θ
of the random effects {βj}, {γk} in (4) must be zero.
On the other hand, under the alternative hypothesis, Y
displays association with either {Xj} or {Zk}, meaning
that either one of the two random effect variances τ, θ
must be non-zero. Thus, to test for association between
each Yi and the sets of variables {Xj}, {Zk}, it is of
interest to test the hypotheses
H0 : Var(β) = Var(γ) = 0 vs. Ha : Var(β) 6= 0 or Var(γ) 6= 0
By proceeding in a similar way as in le Cessie & van
Houwelingen[8] and in Goeman et al.[7] for the one
covariate set case, we can write the test statistic for
these hypotheses as
T 2XZ =
T 2X + T
2
Z − 2ρXZTXTZ
1− ρXZ
, (5)
where TX , TZ are the standardized test statistics com-
puted with only one covariate set in the model defined
by (3), and ρXZ is the correlation between T
2
X and T
2
Z .
A detailed derivation is given in section 2 of the ap-
pendix. Note that if in (5) we take ρXZ ≡ 0, we obtain
the simpler expression
T 2XZ = T
2
X + T
2
Z . (6)
For simplicity, we may ignore the standardization and
the squaring, then write the unscaled test statistic for
two gene sets as
Q(X,Z) ≡ Q(X) +Q(Z). (7)
This makes sense. Indeed, from (2),
Q(X) +Q(Z) =
(Y − µ)t [XXt + ZZt] (Y − µ)
(Y − µ)t(Y − µ)
,
where XXt+ZZt is the matrix in the quadratic form
that would have been obtained if our model had a sin-
gle set of covariates given by the merged set {X,Z},
and with effect modelled by a single vector of ran-
dom effects. In such a case, the design matrix would
have been obtained by binding the columns of X and
Z together and, thus, the unscaled score test statistic
would be given as above.
Thus, the standardized test statistic for two covari-
ate sets is equal to the sum of the individual test statis-
tics per covariate set, if the correlation ρXZ between
the test statistics can be ignored. Similarly for the un-
scaled and unsquared versions of the score test statis-
tics, the test statistic for two gene sets X and Z is
equivalent to the one obtained for a single gene set
formed by {X,Z}.
In practice, some sort of centering and scaling of
Q(X), Q(Z) may be used, especially when covariates
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take values in different ranges, are of very different
sizes and/or display different variances. In such cases,
centering and scaling can ensure the separate sets are
given the correct weights in the combined test statistic
Q(X,Z). This can be done by using the scaled indi-
vidual test statistics as in (6). An alternative is given
in Section 5 of Additional File 1.
Extension to more than two gene sets
A closed analytical form for the score test statistic can
be obtained for any given number of gene sets M , as
shown in section 3 of the appendix. Here we note that
the score test statistic typically is a function of the in-
dividual test statistics and their pairwise correlations.
If the pairwise correlations are ignored, the squared
test statistic forM gene sets can be written as the sum
of the squared and standardized test statistics for the
individual gene sets, generalizing the result obtained
for M = 2. In particular, we note that if unsquared
and non-standardized versions of the test statistics are
used, it is easy to see that the test statistic for any M
number of gene sets is the same one as generated by
a model with a single gene set, formed by merging all
gene sets together.
The role of the correlation
The correlation ρXZ between test statistics for sin-
gle gene sets TX , TZ is an integral part of the score
test statistics for multiple gene sets, as seen above. Al-
though such correlations can be estimated, for example
via re-sampling, this makes computations considerably
more complex. It turns out that correlations between
individual test statistics can be ignored with little loss
of power. Here we give a heuristic argument for this,
and in the Results section we will confirm this in a
simulation study.
We have seen in expression (7) that, if we consider
the unscaled and linear form of test statistics, the score
test statistic for two gene sets Q(X,Z) equals the test
statistic for a single gene set, formed by the union of
all gene sets into a single one, or Q(W ) where W is a
matrix formed by the columns of X,Z bound together.
As such, the test statistic already considers not only
correlation between the covariates in the set and the
dependent variable Yi, but also pairwise correlations
between the covariates in the set, as shown by Goe-
man et al.[10], section 7. Thus, correlations between
the covariates, and between the covariates and the de-
pendent variable, are already considered and catered
for by the score test statistic. Therefore, the explicit
inclusion of the correlations between test statistics for
individual sets is not essential, as these correlations are
already taken into account.
For this reason, and due to its simplicity, we suggest
ignoring the correlation when computing the joint test
statistic. This means using either the unscaled test
statistic (7) or its scaled version (6). We will verify
in simulation studies that the test statistics with and
without the correlation yield similar power, in situa-
tions of practical interest.
Test statistic null distribution
For testing, the distribution of T 2XZ under the null
hypothesis of no association between Yi and X,Z is
needed. Here we will consider the expression (7) for
the combined test statistic. For the single-set testing,
Goeman et al.[11] obtains an expression for the asymp-
totic distribution of Q(X) under a generalized linear
model, which is the exact finite sample distribution un-
der the linear model, as used here. This (asymptotic)
null distribution can be written as a ratio of weighted
sums of χ21 random variables[11].
Our test statistic (7) for two covariate sets X,Z can
be seen as a test statistic for a single covariate set re-
sulting of the union of the two original sets. This means
that the distributions derived in Goeman et al.[11] can
be used for (7).
Note that, in case of applying the test to many sepa-
rate responses {Yi}, such as expression levels of many
different genes, the resulting computational burden of
numerically estimating the distribution per response
may be superior to computing p-values via permuta-
tion. In the cancer examples, we use permutations to
compute p-values for Q(X,Z) for computational ease,
and use the sum of test statistics (7).
Software
Methods presented in this work are implemented in
the Bioconductor package SIM, currently for a single
covariate set, and in the short-term for multiple co-
variate sets. All computations described and applied
in this work used R from at least version 3.0.1 (see
[12] for a recent reference).
Results
Simulation study 1
We run a simulation study to evaluate the power of
the proposed test statistics under various types of ef-
fects. A detailed description of the study setup is given
in Section 1 of the Additional File 2. For completene-
ness, here follows a brief description. The data here is
assumed to consist of two explanatory sets of covari-
ates, {Xj , j = 1, . . . , J} and {Zk, k = 1, . . . ,K}, and
a set of dependent variables {Yi, i = 1, . . . , I}. For
simplicity we assume that I = J = K.
We consider four independent data sets, each in-
volving one set of variables {Yi, Xj , Zk}, with i, j, k =
1, . . . , 1000. Each data set can be seen as a (genomic)
region, here assumed to involve one association type
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between the covariate sets and the dependent variable
Yi for i = 1, . . . , 500, and no association for the re-
maining probes. The associations considered are: re-
gion I, where Yi is associated with {Xj} only, which
we will refer to as “x only”; region II, “additive”, where
both covariate sets affect outcome linearly; region III,
“multiplicative”, where both covariate sets affect out-
come linearly as well as multiplicatively; and region
IV, “split-samples” or “complementary”, where {Yi}
depends upon {Xj} for half of the samples, and for
the other half {Yi} depends upon {Zk}. For each data
set, three sample sizes are considered: 50, 100 and 200
samples.
Within each region, we test for association between
each Yi and the covariate sets {Xj}, {Zk} using both
the test statistics for two gene sets (5), where correla-
tion is estimated via permutation, as well as its sim-
plified expression by ignoring the correlation (6). Note
that these are the scaled versions of the test statistics,
as it is in the expression for T 2XZ that the correlation
ρXZ between T
2
X and T
2
Z appears. Here p-values are
estimated by comparing the observed test statistic to
values obtained after permuting the dependent vari-
able samples 1000 times, and re-computing the test
statistics. For the aims of this particular study, which
is to compare ROC curves, no multiple testing is nec-
essary.
ROC curves were made to evaluate the power of
finding the four effect types (figure 1 for N = 100 -
see supplementary figures 1 and 2 in Additional File 2
for results corresponding to sample sizes 50 and 200).
In all cases, the power yielded with the test statistic
with correlation (5), indicated in purple, is virtually
the same and the one with the test statistic that ig-
nores correlation (6), indicated in pink. This confirms
our arguments, given in the Methods section, that cor-
relation between test individual test statistics need not
be taken into account as it is already intrinsically in-
cluded. Test statistics used displayed acceptable power
to find effects, with the most difficult effect to find be-
ing the complementary. This is related to the nature of
the effect, where one covariate set explains the depen-
dent variable for a few samples, and the second covari-
ate set explains it for another set of samples. Even in
this case, associations can be found if the sample size
is relatively large enough. In our setup, the sample size
of 50 yields power just above random to find effects,
with a clear improvement with N ≥ 100.
Simulation study 2
We have argued that correlation between single-set
test statistics (ρXZ in equation 5) needs not be taken
into account in the two-set test statistic expression,
and we have seen in the above simulation study that,
indeed, test statistics with and without explicitly in-
cluding this correlation yield virtually the same power
to find a variety of effects. However, our simulation
study involved covariate sets X,Z simulated inde-
pendently, so that no significant correlation between
these sets, and ultimately between their correspond-
ing single-set test statistics, would have been expected.
So the question remains of whether correlation would
have an impact on power to find effects, if covariate
sets were correlated.
To answer this question, we perform a second sim-
ulation study where the covariate sets are correlated.
Here we use the same setup as in the first simulation
study presented in the previous section, with the same
regions displaying the same effects. The only difference
is that here Zj = Xj + Uj , where the {Uj} are inde-
pendently and identically distributed normal variables
with mean 0 and standard deviation 1. This leads to a
relatively high positive correlation between {Xj} and
{Zk}, as we can see from figure 2 for N = 100. To find
associations, we use the joint test statistic including
the estimated correlation (5), as well as the simpli-
fied test statistic given by the sum of the non-scaled
single-set test statistics (7).
Our simulation scheme produces highly correlated
data sets. The relatively high correlation between sam-
ples (blue curve in supplementary figure 3) becomes di-
luted when test statistics for individual sets are com-
puted (red curve in supplementary figure 3). This is
due to the fact that individual-set test statistics mea-
sure association with the dependent variables {Yi}. In
cases where {Xj} and {Zk} display similar associa-
tion with {Yi}, such as in the additive region, corre-
lation between Q(X) and Q(Z) will be more similar
to that between the covariate sets. However, in cases
where the sets {Xj} and {Zk} do not display similar
association with the dependent variables, correlation
between Q(X) and Q(Z) will be almost completely
dampened, compared to that between covariate sets
directly. Thus, dampening of the induced correlation
depends on the region/type of association considered.
Nevertheless, some correlation between individual test
statistics remains.
In spite of the correlation between single-set test
statistics, ROC curves produced with the test statis-
tics including the estimated correlation (5), as well
as with the test statistic ignoring the correlation
(tx.2gs.nocor), are virtually identical under additive
or split-samples/complementary effects (figure 2 for
N = 100, see supplementary figures 4 and 5 in Addi-
tional File 2 for N = 50, 200 respectively). This can be
interpreted in two ways. Firstly, as already discussed in
the Methods section, the sum of single-set test statis-
tics Q(X), Q(Z) is equivalent to the test statistic for
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the merged set Q(X,Z). As such, correlation between
covariates, as well as between covariates and response
Yi, are implicitly taken into account by the test statis-
tic. This means that there is no added information
in including the computed correlations explicitly in
the test statistic. Secondly, this result suggests that
the test statistics’ correlations induce similar shifts in
the null and alternative distributions of the joint test
statistics, in such a way that power is ultimately not
affected. Thus, by disregarding the correlation there is
no loss of power to find associations between gene sets
and responses. These conclusions can be drawn for all
sample sizes used here (N = 50, 100, 200).
Still from figure 2, we notice that, if covariate sets
affect the response in a multiplicative way, then there
is a small gain on overall power by taking the correla-
tion into account. However, the difference is negligible
for p ≤ 0.03, where interest mostly lies in practice. In-
deed, since p-values here have not been corrected for
multiple testing, significant associations will be typi-
cally found to have uncorrected p-values in this range.
This conclusion can be extended for the other sample
sizes considered here (N = 50, 200, see supplementary
figures 4 and 5 in Additional File 2).
On the other hand, when a single covariate set is
associated with the response {Yi} and the covariate
sets are correlated with each other, then to take the
correlation into account leads to a power loss. This is
likely due to the fact that, although the covariate sets
are correlated and, thus, their individual test statistics
Q(X) and Q(Z) are also correlated, only {Xj} influ-
ences the responses {Yi}. So, in this case by taking the
correlation explicitly into account, noise is introduced
in the test statistic, leading to a power loss. This power
loss due to using Q(X,Z) is larger than this test statis-
tics’ power gain under a multiplicative effect, and it is
already seen for p-values very close to zero.
The results of this simulation study suggest that the
simplified test statistic, that does not explicitly include
the correlation between single-set test statistics, yields
at least as high power as the test statistic that does
explicitly include the correlation, for the effect types
considered, except for the multiplicative effect, where
it leads to a slight power loss. Here we point out that
the power loss is noticeable for p-values greater than a
threshold larger than zero, although it is not possible
to indicate in practice where this threshold would be.
Colon and breast cancer datasets
Data and definitions
In our simulation studies we have shown that the joint
test statistic Q(X,Z) can test for, and find, different
types of associations between covariate sets and re-
sponses. Here we will see that its relationship with the
individual test statistics Q(X), Q(Z) can help eluci-
date the relative effects of molecular mechanisms un-
der study on the response. To illustrate this, we will
consider colon and breast cancer data sets extracted
from The Cancer Genome Atlas (TCGA). We down-
loaded 125 colon and 173 breast cancer samples, which
had been profiled for DNA copy number (CN), methy-
lation (ME) and gene expression. DNA copy number
data was derived from the Affymetrix SNP 6.0 mi-
croarray and had been segmented. We de-segmented it
to produce individual intensities measured over 3×104
equally-spaced positions on the genome. The level-2
DNA-methylation profiles downloaded had been pro-
duced by the Infinium Human Methylation 27K array,
which produces per probe a m and a u signal, repre-
senting methylated and unmethylated signals respec-
tively. As measurement, we used the logit of the ratio
m/(m + u), to transform the ratios into real-valued
variables as well as correct them for DNA dosage.
The level-2 gene-expression profiles downloaded cor-
respond to lowess-normalized log-ratios obtained us-
ing Agilent 450A arrays, involving 62335 probes with
known genome location.
Here we will consider gene expression as the response
variable, and we will study how DNA copy number and
methylation affect expression levels, both individually
as well as jointly. Specifically, we consider a model
such as (4), where Yi represents the ith gene expression
probe, {Xj} represents the set of copy number probes
that are within 1Mb in either direction of the tran-
scription start site of the gene, and {Zk} represents the
set of methylation probes that are within 50Kb of the
gene’s transciption start site in either direction. These
window sizes are arbitrary and reflect current knowl-
edge on the distance of cis–regulatory effects of copy
number ([3],[13]) and methylation on gene expression
[14].
We computed p-values for Q(X,Z), which we will re-
fer to as the joint test, as well as for the individual test
statistics Q(X), Q(Z), which will be referred to as the
CN test and the ME test, for association between DNA
copy number or methylation with the gene expression.
In all comparisons, we use p-values not corrected for
multiple testing, as the comparisons between different
test results can be more reliably done in this way (in
practice, multiple testing should always be used). As-
sociations for which p ≤ 0.001 were selected. In all
cases, empirical p-values distributions were verified to
be enriched with small p-values, so that in none of the
cases does the set of mRNA probes selected have small
p-values entirely due to chance. Various ratios of the
number of selected tests will be computed, following
definitions in supplementary table 2 (Additional File
2).
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Tables of all mRNA probes tested, with p-values
computed by joint and individual tests, can be found
in Additional File 3 for the colon cancer data, and Ad-
ditional File 4 for the breast cancer data.
Individual and joint copy number and methylation
effects
Individually, copy number changes explain a larger
portion of the gene expression variance than methyla-
tion, notably for the colon cancer data set (see supple-
mentary table 3 in Additional File 2). Interestingly, in
the colon cancer data we find twice as many mRNA ex-
pression probes selected as associated with copy num-
ber (16% of the total) than in the breast cancer data
(8%), despite the latter involving almost 50% more
samples than the former (173 and 125, respectively).
So, copy number changes regulate the expression of
a larger number of genes for colon cancer, compared
with breast cancer. The proportion of mRNA expres-
sion probes selected as being regulated by methylation
changes is comparable in these two data sets (5.4 and
5.2% for colon and breast, respectively).
Results separately per chromosome arm mostly re-
flect the stronger copy number effect in colon cancer
compared with breast cancer, although the relative dif-
ference between colon and breast cancer here varies de-
pending on the chromosome arm. Methylation effects
are, on the other hand, observed in very similar pro-
portions (figure 3 and supplementary tables 4 and 5).
Examples of this are found with 1q and 17q. However,
two chromosome arms are more extreme: 20q and, to
a lesser extent 13q, are outliers in the colon cancer
data set, with a larger proportion of selected associa-
tions with either copy number or methylation than the
remaining arms.
The relationship between the proportions of selected
joint tests for colon and breast cancer (supplementary
figure 6, Additional File 2) reflect mostly the relation-
ship found with the CN test (figure 3, left graph); this
is due to the copy number effect largely influencing the
joint effect.
We can better understand these differences if we now
look at the relationship between tests gene-wise, i.e.
considering test results per gene. For colon cancer, the
joint test yields virtually the same results as the CN
test, for 20q and 13q in colon cancer (see top-left hand-
side graphs of supplementary figures 7 and 8). In ad-
dition, more than 76% of all mRNA probes selected
by ME tests are also selected by CN tests, so that
copy number explains on its own most of gene expres-
sion variability (supplementary figure 9). In contrast,
for breast cancer the joint test selects mRNA probes
that are not selected by the CN test on 20q (supple-
mentary figure 7, top-right), and only between 26 and
37% of the mRNA probes selected by ME tests are
also selected by CN tests (supplementary figure 9 and
supplementary table 6). The fact that, in colon can-
cer, methylation effects mostly overlap with copy num-
ber effects cannot be due to measurement artefact, as
the methylation measurements are corrected for total
DNA. This suggests that copy number drives the asso-
ciations and, as both 13q and 20q often display copy
gains in colon cancer (which is the case in this data),
it follows that those gains are likely to be important
for oncogenesis.
In contrast, 5q, 16p and 16q display a relatively high
proportion of associations with copy number, but not
with methylation, for both cancer types (figure 3).
Here, the joint test selects additional mRNA probes,
not selected by the individual test statistics (see sup-
plementary figure 10 for 5q – results for 16p and 16q
are similar and not shown). In addition, between 18
and 35% of the mRNA probes selected by ME tests are
also selected by the CN test in colon cancer, whereas
in breast cancer these ratios lie between 52 and 64%
(supplementary figure 9). This makes results for 13q
and 20q in colon cancer more remarkable: they yield
the highest percentages of selected CN tests and ME
tests, and the largest overlap of ME tests with CN
tests.
Comparisons between genome-wide or chromosome
arm-wide proportions help picking up trends that dif-
ferentiate these two cancer types, although they obvi-
ously ignore region-specific effects: 17q has commonly
amplified regions in breast cancer with an impact on
gene expression [2], which is not the case for colon can-
cer.
Overlap between individual and joint tests
Since joint test statistics are the sum of individual
ones, results from joint and individual tests naturally
may display some association. The extent of this as-
sociation varies, as it indicates how much of the total
gene expression variability is explained by each indi-
vidual effect. In order to study this, we will consider
the proportion of tests selected both individually as
well as with the joint test, compared to the total of se-
lected joint tests. These are labeled as “CN and joint
overlap” and “ME and joint overlap” for copy num-
ber and methylation respectively, in the supplemen-
tary tables 2-5. When the joint test leads to many
extra discoveries, compared with the individual test,
this proportion is small. If the proportion is close to
1, however, the joint test statistic mostly finds asso-
ciations already identified by the individual test, sug-
gesting that a single molecular profile drives effects on
gene expression.
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The complement of this proportion (obtained by
computing 1-proportion), the ratio of new discover-
ies with the joint test, points out clearly that large
fractions of joint test new discoveries are yielded when
compared with the ME test (figure 4). This was ex-
pected, due to the stronger copy number effect that
the methylation test does not capture on its own, but
that the joint test does. Nevertheless, the advantage
of the joint test is evident as there are new discoveries
with the joint test for all chromosome arms.
The overlap ratios show that, as expected, a rela-
tively large proportion of mRNA probes selected by
joint tests is also selected by the CN test (80% and 70%
for colon and breast, respectively - supplementary ta-
ble 3). In contrast, selected joint tests are also selected
with the ME test at considerably smaller proportions
(29% and 41% for colon and breast, respectively - sup-
plementary table 3). This can be again explained by
the strong copy number effects and, as these are more
pronounced in colon cancer than in breast cancer the
joint test, compared to the CN test, leads to more extra
discoveries in the breast cancer data than in the colon
cancer data. Note that herewith when we refer to a
“selected test” we obviously mean a “selected mRNA
probe by the test”.
Results per chromosome arm mostly reflect the
strong copy number effect, especially for colon can-
cer (figure 5, graphs on top row). Some special pat-
terns appear: for 8p and 8q, mRNA probes selected
by the joint test are, but for a fraction around 10%,
also selected by the CN test, for both cancers. The
overlap between the ME and joint tests is smaller, be-
tween 20 and 27% (supplementary tables 4 and 5). As
most of the mRNA probes selected by the ME test are
also selected by the CN test, especially for 8q, these
arms display for both colon and breast cancers similar
patterns to 20q and 13q for colon cancer (see supple-
mentary figure 9 for an overview, and supplementary
figure 11 for 8q).
Another interesting case is 18p, where virtually all
(99%) selected joint tests also yield significant CN tests
for colon, whilst for breast cancer this proportion is
50%. Furthermore, for colon cancer only 14% of the
selected joint tests are also selected ME tests, whilst
for breast cancer this proportion is 50%. Indeed, in
breast cancer CN and ME tests are selected for differ-
ent mRNA probes: the overlap between significant CN
and ME tests is 0 (supplementary figure 9). Thus, for
genes on 18p, copy number changes drives gene expres-
sion regulation in colon cancer. In contrast, in breast
cancer methylation changes also drives gene expression
regulation, independently of copy number.
Another interesting example is 19q, for which ap-
proximately 63 and 70% of the selected joint tests were
not selected by the CN test individually, for colon and
breast cancer respectively. The same 19q displays the
largest overlap (76 and 70% for colon and breast, resp.)
between selected joint and ME tests, leading us to con-
clude that methylation effects drive gene expression
regulation on 19q, for both cancers. Indeed, methyla-
tion effects dominate the joint test statistic, although
copy number effects are still found for genes that are
not affected by methylation change (supplementary
figure 12), with subsequently little overlap between se-
lected CN and ME tests (supplementary figure 9).
That methylation plays a stronger role in gene ex-
pression regulation in breast cancer, compared with
colon cancer, has thus been made clear. This is par-
ticularly noticeable when we examine the overlap pro-
portions between selected joint and methylation tests;
these represent strong enough effects, although they
may in some cases overlap with selected copy number
tests too. On chromosome 9, in particular, these pro-
portions of overlap are strikingly larger in the breast
cancer data (55 and 51% for 9p and 9q, respectively),
compared with the colon cancer data (23 and 21% for
9p and 9q – see supplementary tables 4 and 5). Inter-
estingly, one of the selected genes on 9p is CDKN2A,
which is mapped by six mRNA probes on the Agilent
expression microarray used. Of these, two are selected
as associated with both the methylation and the joint
tests in the breast cancer data, and two are just above
the selection threshold (p-values ≤ 0.005) with these
two tests. In contrast, in the colon cancer data only
one probe would be selected with a less stringent cut-
off, by the methylation and the joint tests (p ≤ 0.005).
Indeed, methylation and gene expression are associ-
ated in both data sets, although the correlation is more
widely and evenly spread across both methylation as
mRNA-expression probes (supplementary figure 13).
In order to better understand the mechanisms regu-
lating CDKN2A expression, let us consider the mRNA
probe A_23_P17356 which has significant associations
in breast, but not colon, cancer. A total of 49 breast
cancer samples display DNA copy loss, whilst only 6
colon cancer samples display a small loss in this re-
gion (supplementary figures 14–15, top). Note that the
mRNA probe is often not under-expressed for these
samples. If we now sort samples in the methylation
data according to for the copy number data heatmaps,
we see that the samples displaying larger DNA copy
loss (right-hand side) also display hypo-methylation of
about half of the probes which, again, is only observed
for breast cancer (supplementary figures 14–15, bot-
tom). If we now look at scatterplots of A_23_P17356
expression and the 19 methylation probes in the covari-
ate set tests, we notice that many of those display neg-
ative association with mRNA expression in breast can-
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cer, but not in colon, as expected of a functional hyper-
methylation event affecting gene expression (supple-
mentary figures 16–17). In particular, DNA loss is
associated with hypo-methylation of some probes in
breast cancer, but these probes are not correlated with
mRNA expression. Indeed, methylation probes corre-
lated with mRNA expression show no correlation with
DNA copy number. So, in breast cancer methylation
affects CDKN2A expression, independently of DNA
copy number change.
Tests with different conclusions
Clearly mRNA probes for which the joint test statistic
is selected (i.e., has p ≤ 0.001) but one of the individ-
ual associations (CN or ME) is not, may mean that
the other individual association is thus selected, driv-
ing the result of the joint test. This is indeed often the
case, but not for all tests. Indeed, there is a small but
non-negligible proportion of mRNA probes (0.6% for
colon and 1.2% for breast) that is selected by the joint
test, whilst that is not the case with either of the indi-
vidual tests (see line “Joint sel but not CN ME/joint
sel” in supplementary tables 2–3). Such cases tend to
reflect small effects that are spread across multiple co-
variates, in this case both copy number and methyla-
tion probes, and the collection of small effects leads to
a result being selected by considering the larger covari-
ate set. As such, these are worthy of further investiga-
tion. Looking at the results per chromosome arm, we
find that 11p and 17p have relatively high proportions
( 4% and 3% respectively) of effects found only with
the joint test statistic, for the breast cancer data (see
supplementary figure 27 and supplementary table 5 in
Additional File 2).
There are of course mRNA probes that are selected
only by an individual test, but not by the joint test. In-
deed, around 21% of the mRNA probes selected by CN
tests are not selected by the joint test, for both colon
and breast cancers. In such effect dilution occurs, the
conclusion is obviously that copy number affects gene
expression whilst methylation does not, to an extent
that the copy number effect, either not very strong
or only spanning a small subset of the copy number
variables, is no longer enough to drive the result of the
joint test statistic. From the mRNA probes selected by
ME tests, between 15% and 27% are found not to be
selected by the joint test, for colon and breast cancer
respectively.
Most chromosome arms display similar, small dilu-
tion of copy number effects for colon and breast, such
as for example 8q (figure 5, bottom-row graphs). This
was partly expected due to the large overlap between
joint and CN tests, in case of 8q almost total. There
are exceptions, however: almost 100% of the mRNA
probes on 18p selected by the joint test are also se-
lected by the CN test in colon cancer, and yet 12% of
all selected mRNA probes with the CN test were di-
luted by the joint test statistic. For 19q, of all mRNA
probes selected by the CN test, around 57% for colon
and 43% for breast were not selected by the joint
test statistic, whilst for the ME test these proportions
were 1 and 8% respectively. So, 19q is a chromosome
arm where methylation effects dominate the joint test
statistic and, as such, are diluted to a very small ex-
tent; on the other hand, about half of the individual
copy number effects are diluted in the joint test statis-
tic.
Overall, we observed more dilution of methylation
effects in the joint test statistic with the breast can-
cer data, compared with colon (bottom-right hand-side
graph in figure 5). This is likely due to the fact that
the breast cancer displays more methylation effects
but, as these effects are mild, they are more likely
to be diluted in the joint test statistic. The largest
methylation-effect dilutions in the breast cancer data
were observed for 6q, 7p, 8p and 8q. We have already
seen that, for 8p and 8q, at least 92% of the mRNA
probes selected by the joint test are also selected by the
CN test, for both colon and breast cancer. This could
be due to methylation having little effect on gene ex-
pression. What the dilution proportions tell us is that
the copy number effect dominance comes at the cost
of the methylation effect: between 18 and 31% in colon
cancer, and between 53 and 71% in breast cancer, of
the methylation effect is “lost”. This is also evident
from the gene-wise test graphs for these chromosome
arms, as a set of p-values that is near zero for the ME
test, but not for CN or joint tests (supplementary fig-
ures 11 and 19 for 8q and 6q, respectively).
Examples of effects found
Our results highlight a variety of effects of copy num-
ber and methylation explaining gene expression vari-
ability. To illustrate this, we selected probes found
with our tests and examined corresponding patterns
in the data motivating the findings. For each test, we
select probes for which a test had p-value ≤ 0.001.
Firstly, we looked for mRNA probes selected with
the joint test, as well as both CN and ME tests, on
13q, 20q and 8q, in the colon cancer data. We further
refined our search by requiring that the probe had CN
test p-value > 0.1 in the breast cancer data. This led
to 56, 104 and 54 mRNA probes being selected, re-
spectively on 13q, 20q and 8q. Secondly, we looked for
probes that had both ME test and joint test p-values
selected, on 19q in the colon cancer data. We again
further refined the selection by selecting only probes
that had ME test p-value > 0.1 in the breast cancer
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data. This led to 98 mRNA expression probes. From
each one of these four lists, we select a single probe to
illustrate effects found, except for 13q and 20q from
which we will examine two and four probes, respec-
tively. Finally, we consider also one probe mapping to
the gene CDKN2A, for which p-values are just above
cut-off for ME and joint tests, in colon cancer. A list of
the probes selected, with annotation and tests results
in both data sets, can be found in supplementary table
7.
The selection criteria used are likely to find mRNA
probes with strong copy number effects on 13q, 20q
and 8q, as we know these characterize the colon can-
cer data. Indeed, this is what we find, but with an in-
teresting twist: copy number seems to explain mRNA
expression for only part of the samples, with in al-
most all cases a subset of samples with diploid copy
number and yet varying mRNA expression. This is
the case with genes GGT7, PIGU, NUFIP1, WFDC2,
SLC39A4, PCDH20 and IFT52 (figure 6 and supple-
mentary figures 20–25). Since these probes also were
selected on the basis of the ME test, we expect that
methylation is also regulating mRNA expression, in
particular in diploid samples, in spite of the strong
copy number effect. Indeed, we found that, not only
samples with DNA copy gain also have less methyla-
tion, but also diploid samples more often display more
methylation. For these samples, it seems that copy
number and methylation have an additive effect on
mRNA expression. Note, however, that in most cases,
copy number and methylation do not explain mRNA
expression completely, with a few samples displaying
less methylation as well as a copy gain, and yet be-
ing under-expressed compared to the remaining sam-
ples. This suggests that a third mechanism is regulat-
ing mRNA expression for a subset of samples, for ex-
ample down-regulating mRNA expression in samples
with DNA copy gain and less than average methy-
lation, or up-regulating mRNA expression in diploid
samples with more than average methylation. In such
cases, the event of up- or down-regulation of mRNA
expression is thus achieved by different mechanisms de-
pending on the sample, which illustrates the concept
of complementary effects introduced in the simulation
study.
It is interesting to note that the mRNA regula-
tory mechanism just described implies that DNA copy
number and methylation are negatively correlated.
This is the opposite from what we expect if a copy
number change occurs at random, which would alter
methylation in the same direction. This suggests again
that the methylation changes are functional, since they
neither can be a consequence of DNA copy gain nor
are they likely to have occurred by chance (and not be
functional) on the diploid samples.
Not all probes follow this pattern. Probe A_23_P17356,
mapping to gene GDAP1L1 , is interesting because
copy number also separates samples into diploid and
copy gain, but now copy gain samples are under-
expressed compared with diploid ones (figure 7).
Methylation still displays a (negative) association with
gene expression, for at least two probes. It is possible
that methylation is compensating for the DNA copy
gain here, since 20q is very often gained in colon can-
cer.
Finally, the probe selected on 19q on the basis of the
ME and joint tests, mapping to the SLC7A9 , shows
indeed methylation negatively correlated with mRNA
expression (supplementary figure 26). As expected,
DNA copy number is not correlated with mRNA ex-
pression.
The probe chosen mapping to CDKN2A displays a
similar pattern to that for SLC7A9 , with a trend of
over-expression for samples displaying more methyla-
tion by one or both methylation probes. On the other
hand, almost all samples with under-expression dis-
played more methylation with at least one of the two
methylation probes (supplementary figure 27). This
was not observed for the same probe in breast can-
cer samples. We conclude that expression of CDKN2A
is often regulated via methylation, but that this can be
best represented by different mRNA probes, for breast
and colon cancer. Methylation probes showing strong
association with mRNA expression may be the same,
as is here the case.
After observing that methylation plays an impor-
tant role in gene-expression regulation in breast can-
cer, we also looked for genes that had, for the ME test,
p ≤ 0.001 and p > 0.1 in breast and colon cancer, re-
spectively. This yielded 439 genes. In order to make
the selection even stricter, we required that each gene
had at least two mRNA probes satisfying the crite-
rion, which led to 274 genes. This list included gene
MGC29506 , also known as MZB1 . It has been previ-
ously found to be frequently methylated in hepatocel-
lular cancer [15]. Of the 4 mRNA probes mapping to it,
two are methylated above average for all samples (data
not shown). Another gene on this list is RAB40C , a
member of the RAS oncogene family. Of the 6 mRNA
probes mapping to it, 2 are significant and exhibit a
negative correlation between median copy number and
mRNA expression (data not shown).
The above mechanisms illustrate effect types that
can be found by our approach, which has squeezed rel-
evant information from thousands of mRNA probes,
copy number and methylation measurements and
yielded a list of mRNAs for further investigation. Ob-
viously, correlation does not mean causation: further
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research would be needed to verify which of the associ-
ations found indeed is functional. In particular, statis-
tical significance need not lead to biological relevance:
as with any statistical method, there are effects found
of too small a magnitude to be biologically relevant.
Discussion
We have proposed a test to find associations between
a dependent variable and two or more sets of covari-
ates. In the context of studies where multiple molecular
profiles are available for each sample, as for example
gene expression, copy number and methylation, such
a test can be used per gene expression variable to test
for associations with copy number and/or methyla-
tion. These help us better understand molecular mech-
anisms of gene expression regulation, individually and
jointly, as we showed with the colon and breast cancer
TCGA data.
Other methods have been proposed to look for as-
sociations between one molecular profile, and two or
more other profiles. One framework that has been used
by various authors for the two-dataset case (one in-
dependent) and, by some, has been extended to the
three-dataset case, is that of penalized canonical cor-
relations [5],[6],[16]. This framework tries to find (lin-
ear) combinations of the variables in the molecular pro-
files datasets that are (most) strongly correlated. As
such, they are of an exploratory nature, whereas our
approach is meant for inference, pinpointing associa-
tions that are statistically significant. Indeed, canoni-
cal vectors essentially identify sets of variables that are
most strongly correlated. While their correlation may
be considered high, it could still be due to chance, espe-
cially considering the high-dimensionality and sparse-
ness of the data sets. In contrast, our approach takes
the sets of covariates as given, and tests the association
with the dependent variable for statistical significance.
In addition, due to their very nature sparse-canonical
correlation-based approaches are computationally com-
plex, and the complexity increases very quickly with
each added independent dataset, as well illustrated by
Lee et al.[16]. Compounded with the high-dimensions
of the datasets involved, this means that some of them
do not easily scale up. In addition, it can be difficult
to interpret the canonical vectors.
Bayesian approaches have also been proposed to
analyse two datasets (one independent) together [17],[18],[19],
but as such approaches are naturally computationally
complex, they often become prohibitively computa-
tionally complex when used on the whole genome, or
for more than one independent data set. Richardson
et al.[18] try to address the complexity by proposing
a more efficient algorithm for MCMC estimation, al-
though they do not apply their method to more than
two data sets in their paper.
Vaske[20] proposed another method to analyse mul-
tiple molecular profiles simultaneously. Their method
consists first of finding associations between probes
in different data sets and (sets of) pathways. Subse-
quently, their matrix of inferred associations between
samples and pathways is used instead of the entire
dataset in analyses. This leads to a dimension reduc-
tion, helping the later computational task of study-
ing associations with clinical variables. Based on the
reduced data set and on known possible interactions
between molecules, directed graphs are built. This pro-
cess involves discretization of the data set and of the
interactions, to enable establishment of direction in
the graph estimation. As such, their method relies on
pathways used containing information relevant to the
study, as well as biological information about molec-
ular interactions within pathways. This makes for a
much more structured method, that is of particular
interest when specific pathways are under study.
Our method is intentionally less structured. We look
at all molecular data with an open mind, and are able
to find regulatory mechanisms that may not be linked
to any known pathway, or may affect genes involved in
pathways only mildly. So it is preferred in cases when
one wishes to search for regulatory mechanisms affect-
ing gene expression, or even molecular mechanisms as-
sociated as a set to a clinical variable. The lack of
imposed structure makes it more flexible, since we can
easily apply it to study the effect of DNA copy num-
ber and methylation together on expression levels of a
gene, or a protein. Precisely the same model could have
been used to study the effects of SNP genotypes and
methylation too. Indeed, our approach could be used
on the matrix of inferred pathway activities generated
by the approach of Vaske et al.[20], instead of their
proposed graphical model, where we would have ig-
nored the interaction factors. Here all pathways could
be used in a single set of covariates to study relation-
ship with a clinical outcome, for example.
Our approach is computationally simple, involving
at its most complicated matrix multiplications for the
linear case. It is also flexible, in that it may correct
for confounder effects. The extension from two sets
of covariates to more sets is straightforward, once we
ignore correlations between test statistics. Even if cor-
relations were not to be ignored, a closed form for the
test statistic is available once the number of covariate
sets is fixed. One of the reasons why our approach is
simpler is that the focus is on testing, rather than on
model fitting, as do Bayesian approaches, or on find-
ing canonical vectors. This allows for quick, simple and
objective evaluation of results, and easy prioritization
of found associations.
In the TCGA data examples, we tested for associa-
tion between gene expression and both copy number
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and methylation changes, in colon and breast cancer
samples. We observed similarities and differences be-
tween these two cancer types. For some chromosome
arms, such as 1q and 17q, proportions of discover-
ies are similar between the two cancers. This needs
not mean that the same gene expression-regulating
mechanisms are involved, but that genomic changes
of the same type are involved at the same ratio. Also,
copy number and methylation do not necessarily ex-
plain gene expression variation of the same genes, and
the joint test finds additional associations compared to
the individual tests. For other arms, such as 13q and
20q, there are clear differences between the genomic
changes found to affect gene expression in colon and
breast cancer.
Some genes were selected to illustrate patterns
found by the method, which showed some expression-
regulating mechanisms driven by a combination of
copy number and methylation changes. The gene se-
lection aimed at illustrating differences found when
chromosome arms results were compared between the
two cancer types. Researchers interested in other se-
lection criteria can apply those to the whole-genome
results table provided (Additional Files 3 and 4).
The pioneering articles of TCGA colon [21] and
breast [22] cancer samples characterization have of
course already given a detailed overview of molecular
changes observed in these data sets. They have, how-
ever, not looked for complex regulatory mechanisms
as we do here. So, our findings complement theirs, al-
though we must be careful when extending the results
from the samples subset used here to a larger set of
cancer samples, as we cannot guarantee representa-
tiveness.
In the illustrations above we assumed that gene
expression was the molecular phenotype of interest.
Clearly that is not always the case, and other molec-
ular phenotypes of interest include protein expression
profiles. Our method can equally well be applied to
such cases, with the reason for us not to have done so
is the relatively limited number of samples with protein
profiles available. In our experience, a minimum num-
ber of samples needed to yield reliable results is about
20 for the two-dataset case (one independent), but that
of course is very much dependent on the signal-to-noise
ratio in the data sets.
Our approach can also be used in a generalized-linear
model context, where the dependent variables are re-
lated to the sets of covariates via a link function, such
as the logarithm or the logit. This extension is straight-
forward, as we use the framework of the global test
[7],[10]. This allows us for example to consider RNA-
Seq data as dependent variables, if a suitable data
transformation exists such that covariate effects can
represent well variability in the transformed RNA-Seq
data. Ideally, we would like to represent the data vari-
ability using the negative binomial, as done for exam-
ple by the BioConductor packages edgeR ([23]) and
DESeq ([24]), as it handles the data overdispersion
([25]). Note, however, that this is not straightforward
as the negative binomial distribution is not in the ex-
ponential family. This extension is beyond the objec-
tives of this paper and will appear elsewhere.
Another application of interest is to study the impact
of changes in multiple molecular profiles on patients’
survival outcome, a variable formed by time from diag-
nosis to event and event information. This can be done
by means of a Cox proportional-hazards model as an
extension of the global test for this setting proposed
earlier [9].
Conclusions
We propose a method to find effects of multiple molec-
ular profiles on a response, which can be a single clini-
cal variable or a molecular profile. Our method is com-
putationally simple, making it scalable for use over
the entire genome. Its flexibility means it can be used
with a variety of molecular types. It can be very useful
to unravel complex gene expression-regulating mecha-
nisms.
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Figures
Figure 1 ROC curves, simulation study 1. ROC curves to
evaluate power to find four different types of effects between
one dependent variable and two independent covariates sets,
N = 100, Simulation Study 1. Purple lines represent curves for
the the two-sets test statistic including the correlation between
individual test statistics. Pink lines represent curves for the
test statistic computed ignoring the correlation.
Figure 2 ROC curves, simulation study 2. ROC curves
obtained with the test statistics including correlations between
single-set test statistic T 2
XZ
, and with the simplified test
statistic T 2
X
+ T 2
Z
that ignore these correlations (N = 100),
for the Simulation Study 2.
Figure 3 Comparison of copy number and methylation
effects. Proportion of genes selected by their expression
association with copy number (left) and with methylation
(right), for colon (x-axis) and breast (y-axis) cancers, per
chromosome arm.
Figure 4 Joint test new discoveries. Computed as the
proportion of genes with selected expression association with
the joint set of covariates, that was found not to be selected
by either copy number (left-hand side, blue shades) or
methylation (right-hand side, purple shades) separately. Top:
colon cancer. Bottom: breast cancer.
Figure 5 Comparing individual and joint tests: overlap and
dilution. Top row: overlap between individual and joint tests.
Computed as the proportion of genes selected by both its
expression being associated with the joint set of covariates,
formed by both copy number and expression, as well as by
each single set of covariates, per chromosome arm. This
proportion is relative to all selected joint tests. Bottom row:
dilution. Computed as the proportion of selected genes for
expression association with one set of covariates (either copy
number or methylation), that are not selected with the joint
set of covariates, formed by both copy number and expression,
per chromosome arm. The proportion is relative to all selected
tests for association with either copy number (bottom-left) or
methylation (bottom-right).
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Figure 6 Gene GGT7: expression, methylation and copy
number. mRNA expression (y-axis) of one probe mapping to
gene GGT7 in the colon cancer data. Top graphs: methylation
values (logit of beta values) for chosen probes within 50Kb of
the gene start site; point colours represent the dychotomized
copy number (see legend and dashed line in the graph right
below), with blue corresponding to approximately diploid
number of copies; the vertical dashed line represents the
cut-off used to separate samples with more or less methylation.
Middle graphs: median copy number values across all
measurements within the 1 Mb region around the gene start
site; point colours represent the dychotomized methylation
(see legend and dashed line in the graph right above), with
blue corresponding to less methylation; the vertical dashed line
represents the cut-off used to separate samples approximately
diploid from those. Bottom graph: mRNA expression for all
samples, sorted from the smallest to the largest; three plotting
symbols are used per sample to convey dychotomized copy
number (star), methylation probe 1 (upwards triangle) and
methylation probe 2 (downwards triangle); symbol colours are
blue for lower values (diploid copy number, less methylation)
or pink (copy gain, more methylation), as before.
Figure 7 Gene GDAP1L1: expression, methylation and copy
number. mRNA expression (y-axis) of one probe mapping to
gene GDAP1L1 in the colon cancer data. Top graphs:
methylation values (logit of beta values) for chosen probes
within 50Kb of the gene start site; point colours represent the
dychotomized copy number (see legend and dashed line in the
graph right below), with blue corresponding to approximately
diploid number of copies; the vertical dashed line represents
the cut-off used to separate samples with more or less
methylation. Middle graphs: median copy number values
across all measurements within the 1 Mb region around the
gene start site; point colours represent the dychotomized
methylation (see legend and dashed line in the graph right
above), with blue corresponding to less methylation; the
vertical dashed line represents the cut-off used to separate
samples approximately diploid from those. Bottom graph:
mRNA expression for all samples, sorted from the smallest to
the largest; three plotting symbols are used per sample to
convey dychotomized copy number (star), methylation probe 1
(upwards triangle) and methylation probe 2 (downwards
triangle); symbol colours are blue for lower values (diploid
copy number, less methylation) or pink (copy gain, more
methylation), as before.
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Additional file 1 — Details in development of the test statistic
This .pdf file includes details on how the test statistic is obtained, including
a general functional form for the test statistic for any number M of
covariates set and the expression obtained for M = 3.
Additional file 2 — Supplementary tables and figures
This .pdf file contains details about the simulation study setup, as well as
all supplementary figures and tables.
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Additional file 4 – Table of all results for the breast cancer data set
